August 20, 2026 05:00 am (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
Vijay govt calls for action to stop students, youth from joining CJP, Left protests | Kolkata hotel fire kills 9: Bengal Minister Agnimitra Paul targets ex-TMC govt, CESC over licences | Kolkata hotel fire: 9 Bangladeshi nationals, including women and a child, die in massive blaze | Tarun Tejpal faces life term? Goa govt moves Supreme Court after 2013 rape conviction | Supreme Court rejects ‘less painful’ death penalty plea, but leaves door open for future change | ‘Vulgarity and disgust’: DMK attacks Vijay over Trisha salute at I-Day event | ‘Take Gyanesh Kumar to the US’: Congress mocks Trump over praise for India’s voter ID system | Big relief for Imran Khan: Pakistan Supreme Court orders hospital transfer amid health fears | Trump praises India’s voter ID system, pushes SAVE America Act | Trump's shock threat to bomb Oman: US President warns ally over Iran deal and Hormuz crisis
COVID-19
Image: PIB

Momentous feat: PM Modi after world's first DNA based anti-COVID-19 vaccine ZyCov-D gets nod

| @indiablooms | Aug 21, 2021, at 04:36 pm

New Delhi/IBNS: Prime Minister Narendra Modi has lauded the scientists after the world's first DNA based anti-COVID-19 vaccine, ZyCov-D, got approval for an emergency use in India.

The Prime Minister tweeted, "India is fighting COVID-19 with full vigour. The approval for world’s first DNA based ‘ZyCov-D’ vaccine of @ZydusUniverse is a testimony to the innovative zeal of India’s scientists. A momentous feat indeed."

Zydus Cadila Friday received approval for Emergency Use Authorization (EUA) of its COVID-19 vaccine, ZyCoV-D, from the Drug Controller General of India (DCGI) to be administered on children and adults 12 years and above.

Developed in partnership with the Department of Biotechnology, Government of India under the ‘Mission COVID Suraksha’ and implemented by BIRAC, ZyCoV-D has been supported under COVID-19 Research Consortia through National Biopharma Mission for Preclinical studies, Phase I and Phase II Clinical Trials and under the Mission COVID Suraksha for Phase III Clinical Trial.

This three-dose vaccine which when injected produces the spike protein of the SARS-CoV-2 virus and elicits an immune response, which plays a vital role in protection from disease as well as viral clearance.

The plug-and-play technology on which the plasmid DNA platform is based can be easily adapted to deal with mutations in the virus, such as those already occurring.

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.